BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15041382)

  • 1. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil.
    Millán O; Brunet M; Campistol JM; Faura A; Rojo I; Vidal E; Jiménez O; Vives J; Oppenheimer F; Martorell J
    Clin Chem; 2003 Nov; 49(11):1891-9. PubMed ID: 14578321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients.
    Barten MJ; Rahmel A; Garbade J; Richter M; Bittner HB; Dhein S; Mohr FW; Gummert JF
    Transplant Proc; 2005 Mar; 37(2):1360-1. PubMed ID: 15848720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cyclosporine therapeutic monitoring with C2 concentrations in stable renal allograft recipients.
    Díaz JM; Sainz Z; Guirado LL; Montañés R; Picazo M; García-Camín R; Alcaraz A; Solà R
    Transplant Proc; 2003 Aug; 35(5):1783-4. PubMed ID: 12962794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
    Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
    Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients.
    Marcén R; Pascual J; Tato A; Villafruela JJ; Teruel JL; Rivera ME; Tenorio M; Fernández M; Burgos FJ; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1780-2. PubMed ID: 12962793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
    Solari SG; Goldberg LR; DeNofrio D; Shaw LM
    Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.
    Gregoor PJ; de Sévaux RG; Hené RJ; Hesse CJ; Hilbrands LB; Vos P; van Gelder T; Hoitsma AJ; Weimar W
    Transplantation; 1999 Nov; 68(10):1603-6. PubMed ID: 10589962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
    Falck P; Vethe NT; Asberg A; Midtvedt K; Bergan S; Reubsaet JL; Holdaas H
    Nephrol Dial Transplant; 2008 Mar; 23(3):1048-53. PubMed ID: 17956893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
    Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.